TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.

Richard S Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.